Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia.

Ang SO, Chen H, Hirota K, Gordeuk VR, Jelinek J, Guan Y, Liu E, Sergueeva AI, Miasnikova GY, Mole D, Maxwell PH, Stockton DW, Semenza GL, Prchal JT.

Nat Genet. 2002 Dec;32(4):614-21. Epub 2002 Nov 4.

PMID:
12415268
2.

Molecular targets from VHL studies into the oxygen-sensing pathway.

Maynard MA, Ohh M.

Curr Cancer Drug Targets. 2005 Aug;5(5):345-56. Review.

PMID:
16101382
3.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
4.
5.

The von Hippel-Lindau tumor suppressor protein.

Ivan M, Kaelin WG Jr.

Curr Opin Genet Dev. 2001 Feb;11(1):27-34. Review.

PMID:
11163147
6.

The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.

Maxwell PH, Pugh CW, Ratcliffe PJ.

Adv Exp Med Biol. 2001;502:365-76. Review.

PMID:
11950150
7.

von Hippel-Lindau tumor suppressor: not only HIF's executioner.

Czyzyk-Krzeska MF, Meller J.

Trends Mol Med. 2004 Apr;10(4):146-9. Review.

PMID:
15162797
8.

HIF hydroxylation and the mammalian oxygen-sensing pathway.

Safran M, Kaelin WG Jr.

J Clin Invest. 2003 Mar;111(6):779-83. Review. No abstract available.

9.

Recent advances in the molecular biology of congenital polycythemias and polycythemia vera.

Gregg XT, Prchal JT.

Curr Hematol Rep. 2005 May;4(3):238-42. Review.

PMID:
15865879
10.

Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.

Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG Jr, Goldberg MA.

Kidney Int. 1997 Feb;51(2):575-8. Review.

11.

The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Barry RE, Krek W.

Trends Mol Med. 2004 Sep;10(9):466-72. Review. No abstract available.

PMID:
15350900
12.

[Von Hippel-Lindau disease].

Shuin T, Ashida S, Yao M, Kanno H.

Nihon Rinsho. 2000 Jul;58(7):1448-54. Review. Japanese.

PMID:
10921322
13.

Regulation of HIF by the von Hippel-Lindau tumour suppressor: implications for cellular oxygen sensing.

Mole DR, Maxwell PH, Pugh CW, Ratcliffe PJ.

IUBMB Life. 2001 Jul;52(1-2):43-7. Review.

14.

Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.

Maynard MA, Ohh M.

Am J Nephrol. 2004 Jan-Feb;24(1):1-13. Epub 2003 Dec 3. Review.

PMID:
14654728
15.
17.

Molecular pathogenesis of the von Hippel-Lindau hereditary cancer syndrome: implications for oxygen sensing.

Yang H, Kaelin WG Jr.

Cell Growth Differ. 2001 Sep;12(9):447-55. Review. No abstract available.

18.

Oxygen homeostasis and cancer: insights from a rare disease.

Maxwell PH.

Clin Med (Lond). 2002 Jul-Aug;2(4):356-62. Review.

PMID:
12195866
19.

Congenital polycythemias/erythrocytoses.

Gordeuk VR, Stockton DW, Prchal JT.

Haematologica. 2005 Jan;90(1):109-16. Review.

20.

Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation.

Maxwell PH, Pugh CW, Ratcliffe PJ.

Exp Nephrol. 2001;9(4):235-40. Review.

PMID:
11423722

Supplemental Content

Support Center